Themis Medicare Limited Asset Resilience Ratio
Themis Medicare Limited asset resilience ratio. Themis Medicare Limited (THEMISMED) has an Asset Resilience Ratio of 1.84% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Themis Medicare Limited (THEMISMED) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Themis Medicare Limited (2006–2026)
Asset resilience ratio of Themis Medicare Limited from 2006 to 2026. This chart shows how Themis Medicare Limited's Asset Resilience Ratio has changed over time. Read Themis Medicare Limited total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Themis Medicare Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Themis Medicare Limited assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs110.23 Million | 1.84% |
| Total Liquid Assets | Rs110.23 Million | 1.84% |
Asset Resilience Insights
- Limited Liquidity: Themis Medicare Limited maintains only 1.84% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Themis Medicare Limited Industry Peers by Asset Resilience Ratio
Compare Themis Medicare Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Themis Medicare Limited Asset Resilience Ratio by Year (2006–2026)
Themis Medicare Limited asset resilience ratio by year from 2006 to 2026. The table below shows the annual Asset Resilience Ratio data for Themis Medicare Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 1.84% | Rs110.23 Million ≈ $1.19 Million |
Rs5.98 Billion ≈ $64.66 Million |
+0.78pp |
| 2025-03-31 | 1.07% | Rs62.81 Million ≈ $679.22K |
Rs5.88 Billion ≈ $63.59 Million |
+1.07pp |
| 2024-03-31 | 0.00% | Rs33.00K ≈ $356.88 |
Rs5.66 Billion ≈ $61.26 Million |
-3.42pp |
| 2023-03-31 | 3.42% | Rs176.01 Million ≈ $1.90 Million |
Rs5.14 Billion ≈ $55.58 Million |
+0.82pp |
| 2022-03-31 | 2.61% | Rs111.62 Million ≈ $1.21 Million |
Rs4.28 Billion ≈ $46.26 Million |
+2.61pp |
| 2021-03-31 | 0.00% | Rs33.00K ≈ $356.88 |
Rs3.71 Billion ≈ $40.14 Million |
0.00pp |
| 2020-03-31 | 0.00% | Rs33.00K ≈ $356.88 |
Rs3.50 Billion ≈ $37.84 Million |
-1.24pp |
| 2019-03-31 | 1.24% | Rs39.04 Million ≈ $422.24K |
Rs3.14 Billion ≈ $33.97 Million |
+0.01pp |
| 2018-03-31 | 1.24% | Rs37.72 Million ≈ $407.96K |
Rs3.05 Billion ≈ $33.01 Million |
+0.90pp |
| 2017-03-31 | 0.34% | Rs10.55 Million ≈ $114.08K |
Rs3.10 Billion ≈ $33.50 Million |
+0.59pp |
| 2016-03-31 | -0.25% | Rs-7.00 Million ≈ $-75.65K |
Rs2.76 Billion ≈ $29.86 Million |
-0.16pp |
| 2015-03-31 | -0.09% | Rs-2.62 Million ≈ $-28.35K |
Rs2.79 Billion ≈ $30.21 Million |
0.00pp |
| 2014-03-31 | -0.09% | Rs-2.62 Million ≈ $-28.29K |
Rs2.85 Billion ≈ $30.81 Million |
+0.00pp |
| 2013-03-31 | -0.10% | Rs-2.61 Million ≈ $-28.18K |
Rs2.73 Billion ≈ $29.57 Million |
-6.87pp |
| 2006-03-31 | 6.77% | Rs106.63 Million ≈ $1.15 Million |
Rs1.57 Billion ≈ $17.02 Million |
-- |
About Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It provides active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, a… Read more